Skip to main content
TipRanks
Go Ultimate75% OFF

Sinopharm Tech Holdings Limited (8156) Stock Price & Analysis

0 Followers

8156 Stock Chart & Stats

HK$0.15HK$0.02(11.68%)
At close: 4:00 PM GMT+8
HK$0.125HK$0.15HK$0.175HK$0.2Aug 17Aug 28Sep 9Sep 23Oct 9Oct 22Nov 9
Day’s Range
HKD 0.11 - HKD 0.16
52-Week Range
HKD 0.06 - HKD 0.36
Previous Close
HKD 0.14
Volume
N/A
Average Volume (3M)
31.53K
Market Cap
HKD 96.96M
Enterprise Value
HKD 173.64M
Total Cash (Recent Filing)
HKD 5.62M
Total Debt (Recent Filing)
HKD 30.73M
Price to Earnings (P/E)
―
Beta
0.32
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt Reduction

Debt has declined from prior-year levels, which is a constructive balance-sheet development and could gradually reduce financing pressure if sustained. However, the improvement remains limited because debt is still meaningful relative to assets and the company continues to have negative equity.

Improving Free Cash Flow Trend

The year-over-year improvement in free cash flow indicates some progress in cash management compared with the preceding period. If maintained, this could support operations and eventual deleveraging, although current cash generation remains insufficient to provide dependable financial support.

Losses Less Severe Than Earlier Years

Although the company remains unprofitable, losses are less severe than the notably weaker results reported in 2021 and 2022. This suggests some historical recovery in earnings performance, but the latest revenue decline and negative margins show that the improvement is not yet durable.

Bears Say

Sharp Revenue Contraction

The steep 2026 revenue decline highlights significant instability in the company’s commercial performance and weakens earnings visibility. A contraction of this magnitude can reduce operating leverage, limit reinvestment capacity, and make a sustained recovery more difficult over the next several quarters.

Negative Equity And Balance-Sheet Stress

Persistently negative shareholders’ equity materially restricts financial flexibility and indicates that liabilities exceed the recorded asset base. Meaningful debt alongside this equity deficit increases balance-sheet vulnerability and may constrain the company’s ability to fund operations or pursue growth internally.

Unprofitable Operations

Low gross margins combined with negative operating and net margins show that the core business is not currently converting revenue into sustainable earnings. Continued operating losses weaken internal funding capacity and make financial improvement dependent on a meaningful recovery in revenue or margins.

8156 FAQ

What was Sinopharm Tech Holdings Limited’s price range in the past 12 months?
Sinopharm Tech Holdings Limited lowest stock price was HK$0.06 and its highest was HK$0.36 in the past 12 months.
What is Sinopharm Tech Holdings Limited’s market cap?
Sinopharm Tech Holdings Limited’s market cap is HK$96.96M.
When is Sinopharm Tech Holdings Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sinopharm Tech Holdings Limited’s earnings last quarter?
Sinopharm Tech Holdings Limited released its earnings results on Sep 24, 2026. The company reported -HK$0.009 earnings per share for the quarter.
Is Sinopharm Tech Holdings Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sinopharm Tech Holdings Limited pay dividends?
Sinopharm Tech Holdings Limited does not currently pay dividends.
What is Sinopharm Tech Holdings Limited’s EPS estimate?
Sinopharm Tech Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Tech Holdings Limited have?
Sinopharm Tech Holdings Limited has 633,693,050 shares outstanding.
What happened to Sinopharm Tech Holdings Limited’s price movement after its last earnings report?
Sinopharm Tech Holdings Limited reported an EPS of -HK$0.009 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sinopharm Tech Holdings Limited?
Currently, no hedge funds are holding shares in HK:8156
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology